MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co EBIT Margin

The EBIT Margin (Operating Margin) of MicroTech Medical (Hangzhou) Co (2235.HK) as of Oct 27, 2026 is 6.65 %. In the previous year, EBIT Margin (Operating Margin) was -18.07 % — a change of -136.82% (higher).

EBIT Margin

6.65 %

YoY

-136.82%

Last updated:

EBIT Margin (Operating Margin) of MicroTech Medical (Hangzhou) Co is 2025 6.65 % . EBIT Margin (Operating Margin) of MicroTech Medical (Hangzhou) Co was 2024 -18.07 % . It decreases by -136.82% higher compared to the previous year.

MicroTech Medical (Hangzhou) Co's operating (EBIT) margin stands at 6.7%, up from -39.7% several years earlier.

The MicroTech Medical (Hangzhou) Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-160.65 CNY
Jan 1, 2020
-194.57 CNY
Jan 1, 2021
-39.74 CNY
Jan 1, 2022
-18.55 CNY
Jan 1, 2023
-48.43 CNY
Jan 1, 2024
-18.07 CNY
Jan 1, 2025
6.65 CNY
The MicroTech Medical (Hangzhou) Co EBIT Margin history
YEAREBIT MarginYoY
6.65 %-136.82%
-18.07 %-62.68%
-48.43 %+161.06%
-18.55 %-53.32%
-39.74 %-79.58%
-194.57 %+21.12%
-160.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

EBIT Margin (Operating Margin) of MicroTech Medical (Hangzhou) Co is 6.65 % in 2025.

EBIT Margin (Operating Margin) of MicroTech Medical (Hangzhou) Co changed from -18.07 % to 6.65 %, representing a -136.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s MicroTech Medical (Hangzhou) Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co